⌘K
t
| Date | 17 Nov 2023 |
| Time | 15:56:07 |
| Category | AGMs and other meetings |
| ID | 8806T |
Renalytix plc
("Renalytix" or the "Company")
Publication of Annual Report 2023 and Notice of 2023 Annual General Meeting
LONDON and SALT LAKE CITY, UT November, 17 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Annual Report for the year ended 30 June 2023 and the Notice of 2023 Annual General Meeting ("AGM") have now been published on the Company's website: https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports and https://investors.renalytix.com/news-and-events/documents-and-presentations, and posted to shareholders who have not consented to receive electronic communications.
The AGM will be held in-person on 15 December 2023 at 15.30 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.
To help with practical arrangements for the AGM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8790.
For further information, please contact:
|
Renalytix plc |
|
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
Gary Clarence / Shalin Bhamra |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
|
|
|
|
CapComm Partners |
|
|
Peter DeNardo |
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.